We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 1,752

Best method: the New Act
  • FB Rice
  • Australia
  • May 22 2017

Any applicant for patent protection in Australia must disclose the best method for performing the invention known to it at the time of filing a

Intervet chew on ownership of an invention in Australian patent opposition proceedings
  • Baldwins
  • Australia
  • May 18 2017

This case concerns whether or not the rights to an invention of an Australian patent application had been successfully transferred from the inventors

Australian Government’s compensation claim against pharma patentees rumbles on
  • Allen & Overy LLP
  • Australia
  • May 18 2017

Commonwealth of Australia v Sanofi 2017 FCA 382 is the latest development in the Australian Government’s bid to recover substantial compensation

Amendments to a patent during court proceedings - how much transparency is required?
  • Shelston IP Pty Ltd
  • Australia
  • May 15 2017

In Apotex Pty Ltd v ICOS Corporation 2017 FCA 466, the Federal Court has provided guidance regarding the level of disclosure required by a patentee

An offer not to be refused: the cost(s) of unreasonable rejection of an offer of compromise
  • Clayton Utz
  • Australia
  • May 11 2017

Following its landmark damages decision for patent infringement in Bayer Pharma Aktiengesellschaft v Generic Health Pty Ltd 2017 FCA 250, the

Bayer awarded indemnity costs against Generic Health in Yasmin patent litigation
  • Shelston IP Pty Ltd
  • Australia
  • May 8 2017

Earlier this year Jagot J of the Federal Court of Australia ordered Generic Health to pay Bayer $25,437,966 in damages plus interest to compensate

Britax overruled - Federal Court sets record straight for infringement of innovation patents
  • K&L Gates
  • Australia
  • May 4 2017

The Full Court of the Federal Court’s decision in Coretell Pty Ltd v Australian Mud Company Pty Ltd 2017 FCAFC 54 has clarified the date from which

Another small victory for Australian Government in its pursuit of damages for PBS “over-payments” during interlocutory injunction period
  • Shelston IP Pty Ltd
  • Australia
  • May 2 2017

The Australian Government has had another small victory in the most recent interlocutory decision in the clopidogrel damages enquiry, which is likely

Pfizer loses legal bid for information from Samsung Bioepis about biosimilar BRENZYS - What it means
  • Griffith Hack
  • Australia
  • May 1 2017

Pfizer has lost a bid in the Federal Court of Australia to access Samsung Bioepis' confidential material about how it produces its biosimilar BRENZYS

Off to a running start? Federal Court of Australia permits generic manufacturer to make PBS application before patent expiry
  • King & Wood Mallesons
  • Australia
  • April 28 2017

Can a manufacturer apply for Pharmaceutical Benefits Scheme (PBS) approval for a generic drug before the patent has expired? Justice Nicholas held in